Cell therapy developer Hopstem completed a $40m Eli Lilly-backed series B round while cybersecurity technology developer SlashNext secured $26m from investors including Telia and Ayala Group.

Funding

Cayman Islands-registered cell therapy developer Hopstem closed almost $40m in series B funding yesterday from investors including Lilly Asia Ventures, a corporate venturing vehicle for pharmaceutical firm Eli Lilly. The round was led by an undisclosed venture capital firm and also featured YuanBio Venture Capital. It came after YuanBio led a $15.7m series A-plus-plus round for the company in May this year that included Longmen Capital and Huacheng Venture Capital.

US-based cybersecurity software provider SlashNext has received $26m in…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn